This study aimed to clarify the clinical significance of drug-resistant HBV in nucleoside/nucleotide analogue (NA)-naive Chinese patients with chronic HBV infection in real clinical practice.
Methods
A total of 845 NA-naive patients who were admitted to Beijing 302 Hospital between July 2007 and March 2012 were included in the study. HBV drug-resistant mutations were examined by direct sequencing of the viral reverse transcriptase gene and verified by clonal sequencing. Phenotypic analysis of viral replication capacity and drug susceptibility were performed by measuring viral replicative intermediate level in 1.1-mer mutant or wild-type HBV amplicon-transfected HepG2 cells in absence or presence of serially diluted drugs.
Results
Drug-resistant mutations were detected in 2.01% (17/845) of the patients by direct sequencing, including 15 with lamivudine-resistant mutations (rtM204V, rtM204I), one with adefovir-resistant mutation (rtA181V), and one with both lamivudine- and adefovir-resistant mutations (rtA181V, rtM204I). Clonal sequencing identified 13 drug-resistant HBV strains: rtL80I+M204I, rtL80I+M204V, rtL180M+M204I, rtL180M+M204V, rtM204I, rtM204V, rtL80I+L180M+M204I, rtL80I+L180M+M204V, rtA181V, rtA181V+M204I, rtA181T+N236T, rtA181V+N236T and rtN236T. Phenotypic analysis showed that two preexisting lamivudine-resistant strains (rtL80I+M204I, rtL180M+M204V) had >1,000-fold resistance to lamivudine, and one pre-existing adefovir-resistant strain (rtA181V+N236T) had 15.4-fold resistance to adefovir compared with the wild-type strain. A follow-up study showed that the presence of pre-existing rtM204I strain in one patient increased from 20% at baseline to 85% after 13 months of entecavir treatment with corresponding recession of wild-type strain in the viral pool.
Conclusions
The incidence of drug-resistant HBV mutations was low in NA-naive Chinese HBV-infected patients. Pre-existing mutants had similar resistance characteristics to those from NA refractory patients.
References
1.
European Association for the Study of the Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
2.
Chinese Society of Hepatology and Chinese Society of Infectious Diseases.[The guideline of prevention and treatment for chronic hepatitis B (2010 version)].Zhonghua Gan Zang Bing Za Zhi2011; 19: 13–24. Chinese.
3.
ZhuangH., WengX.[Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management.]Zhonghua Gan Zang Bing Za Zhi2013; 20: 15–22. Chinese.
4.
SayanM., AkhanS.C., MericM.Naturally occurring aminoacid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B.J Viral Hepat2010; 17: 23–27.
5.
MirandolaS., CampagnoloD., BortolettoG.Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.J Viral Hepat2011; 18: e212–e216.
6.
LeeS.H., KimH.S., ByunI.S.Pre-existing YMDD mutants in treatment-naive patients with chronic hepatitis B are not selected during lamivudine therapy.J Med Virol2012; 84: 217–222.
7.
CuestasM.L., RiveroC.W., MinassianM.L.Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina.Antiviral Res2010; 87: 74–77.
8.
Margeridon-ThermetS., ShulmanN.S., AhmedA.Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.J Infect Dis2009; 199: 1275–1285.
9.
PastorR., HabersetzerF., Fafi-KremerS.Hepatitis B virus mutations potentially conferring adefovir/ tenofovir resistance in treatment-naive patients.World J Gastroenterol2009; 15: 753–755.
10.
HanY., HuangL.H., LiuC.M.Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.J Gastroenterol Hepatol2009; 24: 1417–1423.
11.
VutienP., TrinhH.N., GarciaR.T.Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients.Clin Gastroenterol Hepatol2014; 12: 1363–1370.
12.
TanY., DingK., SuJ.The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.PLoS ONE2012; 7: e32789.
13.
LiuB.M., LiT., XuJ.Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients.Antiviral Res2010; 85: 512–519.
14.
JardiR., Rodriguez-FriasF., SchaperM.Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.J Viral Hepat2007; 14: 835–840.
15.
PollicinoT., IsgroG., DiS.R.Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.Antivir Ther2009; 14: 649–654.
16.
XuZ., LiuY., XuT.Acute hepatitis B infection associated with drug-resistant hepatitis B virus.J Clin Virol2010; 48: 270–274.
17.
LiuY., WangC., ZhongY.Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.J Viral Hepat2011; 18: e29–e39.
18.
LiX., WangL., ZhongY.Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients.J Clin Microbiol2010; 48: 4363–4369.
19.
ZoulimF.In vitro models for studying hepatitis B virus drug resistance.Semin Liver Dis2006; 26: 171–180.
20.
JiD., LiuY., LiL.The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.J Clin Virol2012; 54: 66–72.
21.
YimH.J., HussainM., LiuY., WongS.N., FungS.K., LokA.S.Evolution of multi-drug resistant hepatitis B virus during sequential therapy.Hepatology2006; 44: 703–712.
22.
HayashiK., KatanoY., IshigamiM.Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains.J Gastroenterol Hepatol2010; 25: 745–749.
23.
BaxaD.M., ThekdiA.D., GolembieskiA.Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States.J Hepatol2013; 58: 212–216.
24.
GhanyM.G., DooE.C.Antiviral resistance and hepatitis B therapy.Hepatology2009; 49: S174–S184.
25.
ThaiH., CampoD.S., LaraJ.Convergence and coevolution of hepatitis B virus drug resistance.Nat Commun2012; 3: 789.
26.
YangH., WestlandC.E., DelaneyW.E.IVResistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.Hepatology2002; 36: 464–473.
27.
LokA.S., ZoulimF., LocarniniS.Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.Hepatology2007; 46: 254–265.
SvarovskaiaE.S., CurtisM., ZhuY.Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.J Viral Hepat2013; 20: 131–140. e89015.
30.
LiuY., XuZ., WangY.rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.PLoS ONE2014; 9: e89015.
31.
LiuY., LiuW., LiX.Screening and identification of a novel adefovir dipivoxil-resistance-associated mutation rtN236V of hepatitis B virus (HBV) from a large cohort of HBV-infected patients.Antivir Ther2014; 19: 551–558.
32.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues.Gastroenterology2009; 137: 1593–1608.
33.
LiuY., WangC., ZhongY.Evolution and suppression of hepatitis B virus strains with genotypic multi-drug resistance to lamivudine, adefovir and entecavir in a patient with chronic hepatitis B.Antivir Ther2010; 15: 1185–1190.
34.
Rodriguez-FríasF., TaberneroD., QuerJ.Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.PLoS ONE2012; 7: e37874.
